Shots:

• The P-III (DREAMS-2) trial assesses the safety & efficacy of mazdutide (4mg, 6mg) vs dulaglutide (1.5mg) in T2D Chinese patients (n=731) having inadequate glycemic control with metformin alone or its combinations
• The study after 28wks. depicted improved HbA1c level from baseline confirming the superiority of mazdutide. Statistical superiority was seen in HbA1c change & percent change in body wt. from baseline, patient proportion with HbA1c <7.0% & ≥5% wt. loss
• Mazdutide is under review for chronic weight management with the NMPA. The company anticipates P-III (DREAMS-1) study results in mid-2024 with an NDA submission for T2D to the CDE. The DREAMS-1 & DREAMS-2 data analysis will be published in academic congresses or clinical journals

Ref: Innovent | Image: Innovent

Related News:- Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com